Getein Biotech (SHSE:603387) Beneish M-Score: -2.84 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603387 Getein Biotech Inc SHSE:603387
77 GF Score
Price ¥8.96
GF Value ¥7.57
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Getein Biotech Beneish M-Score?

Getein Biotech SHSE:603387 +0.67% 77 Beneish M-Score is -2.84 as of Aug. 02, 2026. GuruFocus rates SHSE:603387 with a GF Score™ of 77/100 and a GF Value™ of ¥7.57 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 762 Medical Devices & Instruments companies, Getein Biotech ranks better than 71.92% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.84 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Getein Biotech's Beneish M-Score or its related term are showing as below:

SHSE:603387' s Beneish M-Score Range Over the Past 10 Years
Min: -2.91   Med: -2.17   Max: 1.65
Current: -2.84

During the past 13 years, the highest Beneish M-Score of Getein Biotech was 1.65. The lowest was -2.91. And the median was -2.17.


Getein Biotech Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Getein Biotech's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Getein Biotech Beneish M-Score Chart

Getein Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.53 -1.92 -2.54 -2.76 -2.77

Getein Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.86 -2.91 -2.68 -2.77 -2.84

SHSE:603387 vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Getein Biotech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Getein Biotech Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Getein Biotech's Beneish M-Score falls into.


SHSE:603387
77GF Score
Getein Biotech Inc SHSE:603387
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Getein Biotech Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Getein Biotech for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8896+0.528 * 1.0306+0.404 * 0.5898+0.892 * 0.9887+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6023+4.679 * -0.049679-0.327 * 0.8079
=-2.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥355 Mil.
Revenue was 267.501 + 294.025 + 244.997 + 268.544 = ¥1,075 Mil.
Gross Profit was 188.168 + 211.741 + 166.67 + 167.226 = ¥734 Mil.
Total Current Assets was ¥2,318 Mil.
Total Assets was ¥3,699 Mil.
Property, Plant and Equipment(Net PPE) was ¥723 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥78 Mil.
Total Current Liabilities was ¥722 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1 Mil.
Net Income was 76.303 + 60.118 + 51.735 + 44.501 = ¥233 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 72.674 + 157.3 + 88.106 + 98.332 = ¥416 Mil.
Total Receivables was ¥404 Mil.
Revenue was 244.148 + 284.974 + 262.157 + 296.085 = ¥1,087 Mil.
Gross Profit was 188.353 + 195.506 + 183.089 + 197.93 = ¥765 Mil.
Total Current Assets was ¥1,879 Mil.
Total Assets was ¥3,723 Mil.
Property, Plant and Equipment(Net PPE) was ¥721 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥131 Mil.
Total Current Liabilities was ¥899 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(355.091 / 1075.067) / (403.732 / 1087.364)
=0.330297 / 0.371294
=0.8896

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(764.878 / 1087.364) / (733.805 / 1075.067)
=0.703424 / 0.682567
=1.0306

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2318.37 + 722.525) / 3698.843) / (1 - (1879.187 + 720.97) / 3722.969)
=0.177879 / 0.30159
=0.5898

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1075.067 / 1087.364
=0.9887

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 720.97)) / (0 / (0 + 722.525))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(77.938 / 1075.067) / (130.89 / 1087.364)
=0.072496 / 0.120374
=0.6023

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.224 + 722.363) / 3698.843) / ((2.465 + 899.068) / 3722.969)
=0.195625 / 0.242154
=0.8079

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(232.657 - 0 - 416.412) / 3698.843
=-0.049679

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Getein Biotech has a M-score of -2.84 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.84 mean?
Getein Biotech (SHSE:603387) has a Beneish M-Score of -2.84 as of Aug. 02, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Getein Biotech and its competitors. According to the industry distribution chart, Getein Biotech ranks #214 out of 762 companies in the Medical Devices & Instruments industry, placing it in the top 28.1%.
Is Getein Biotech's Beneish M-Score too high?
Getein Biotech's current Beneish M-Score is -2.84. Based on the distribution chart, Getein Biotech ranks #214 out of 762 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Getein Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #214 out of 762 companies for Beneish M-Score. This puts Getein Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Getein Biotech and its competitors. Getein Biotech's current Beneish M-Score is -2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.57, compared to a current price of ¥8.96 — trading 18.4% above its estimated fair value. The current Beneish M-Score is -2.84. Getein Biotech's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Beneish M-Score is -2.84 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Getein Biotech (SHSE:603387) Overvalued in 2026?

Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued. The current stock price of ¥8.96 is trading 18.4% above its estimated GF Value™ of ¥7.57. GuruFocus considers Getein Biotech to be Modestly Overvalued.

Key valuation signals for SHSE:603387:

  • Beneish M-Score: -2.84
  • GF Value™: ¥7.57 vs. price of ¥8.96 (18.4% above fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Getein Biotech Business Description

Address No. 9 Bofu Road, Luhe District, Nanjing, CHN, 211505
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
77GF Score

Get the complete analysis for SHSE:603387

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.96
Price
¥7.57
GF Value